TCGN yields 2000000.00% · ABBV yields 3.06%● Live data
📍 TCGN pulled ahead of the other in Year 1
Combined, TCGN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TCGN + ABBV for your $10,000?
Technology General Corporation engages in the manufacture of deep-drawn metal-formed products, and ice crushing and shaving equipment; manufacture and distribution of spray coating and industrial mixer systems; and sale of its products to various users primarily in the United States. It operates in three divisions: Precision Metalform, Eclipse Systems, and Clawson Machine. The Precision Metalform division manufactures various deep drawn metal components used primarily in the writing instruments industry and cosmetic industry. The Eclipse Systems division manufactures products, including spray coating systems, and industrial air-driven and electric mixers. Its spray coating systems are used primarily for coating industrial products and the industrial mixers are used in the chemical and food processing industries. The Clawson Machine division produces a line of ice crushing equipment that is used by hotels, restaurants, cruise liners, and related sectors. The company markets its products directly and through a network of distributors. It also owns and leases its buildings to industrial tenants. The company was incorporated in 1957 and is based in Franklin, New Jersey.
Full TCGN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.